Justa thought to share for us long-term shareholders (and new shareholders alike) about the recent increase incommunication from management.
1.We did not have a fully subscribed shareholder placement.
2.DrHowie McKibbon spruiking Australian "investors are comfortable backing earlystage, high-risk biotechs" a couple of days ago.
3.Now the investorpresentation of the potential of SB and Revenues.
4.Is $8Min cash reserves enough to commercialise on the good news that we are about to be received / announced?
I amsuggesting for discussion that management are preparing the market for a capital raise forcommercialisation, given the good news of the FDA approval.
Watchingwith an open mind and has anyone else had this thought bubble?
Gilp
Ann: Webinar Updated Commercial Research for Sofpironium Bromide, page-7
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.015(4.05%) |
Mkt cap ! $699.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $1.537M | 4.028M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 91664 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |